NovaBay Pharmaceuticals, Inc. (NBY) - Dilution Analysis

10-Q filing | 26.0M shares outstanding

8-K filing: NovaBay Pharmaceuticals, Inc. entered into a Securities Purchase Agreement to issue and sell pre-funded warrants to purchase 837,696,130 shares of common stock for gross proceeds of approximately $134 million. ($134.0M proceeds)

S-3/A filing: The company may offer and sell up to $200,000,000 of any combination of common stock, preferred stock, debt securities, warrants or units.

10-Q filing | 126.0M shares outstanding

8-K filing: David Lazar transferred his rights to purchase Series D and Series E Preferred Stock to R01 Fund LP and Framework Ventures IV L.P., subject to stockholder approval.

S-3 filing: The company is filing an S-3 to register the offering of up to $200,000,000 of any combination of common stock, preferred stock, debt securities, warrants or units.

8-K filing: NovaBay Pharmaceuticals, Inc. declared a special cash dividend of $0.80 per share for its common stock, payable on September 29, 2025, to stockholders of record on September 15, 2025; also, David E. Lazar completed the purchase of 481,250 shares of Series D Preferred Stock at $8.00 per share for $3.85 million. ($3.85M proceeds)

10-Q filing | 5.8M shares outstanding

10-Q filing | 5.4M shares outstanding

10-K filing | 5.8M shares outstanding

8-K filing: NovaBay Pharmaceuticals, Inc. entered into settlement agreements with Sabby Volatility Warrant Master Fund Ltd., Bigger Capital Fund, LP, and District 2 Capital Fund LP, involving warrant exercises and warrant purchases. ($2.16M proceeds)

10-Q filing | 4.9M shares outstanding

10-Q filing | 4.9M shares outstanding

S-1/A filing: The company is offering shares of common stock, Series F-1 warrants, Series F-2 warrants, Series F-3 warrants and pre-funded warrants.

S-1/A filing: The company is offering shares of its common stock, Series F-1 warrants, Series F-2 warrants and pre-funded warrants.

S-1/A filing: The company is offering common stock, Series F-1 warrants, Series F-2 warrants, and pre-funded warrants.

S-1 filing: The filing is an S-1 relating to the offering of common stock, Series F warrants, and pre-funded warrants, as well as the common stock issuable upon exercise of the warrants.

S-1 filing: This prospectus relates to the resale of up to 298,355 shares of NovaBay Pharmaceuticals, Inc.'s common stock, issuable upon the exercise of warrants and conversion of Unsecured Convertible Notes.

8-K filing: NovaBay Pharmaceuticals, Inc. entered into letter agreements with existing warrant holders to exercise warrants at a reduced price of $2.50, resulting in the issuance of approximately 90,381 shares of Common Stock and gross proceeds of approximately $225,952 to the Company. ($0.23M proceeds)

8-K filing: Stock split 1-for-35 | Outstanding: 32,025,000 → 914,954

10-Q filing | 32.0M shares outstanding

10-K filing | 11.2M shares outstanding

8-K filing: NovaBay Pharmaceuticals entered into a First Amendment to Security Agreement and a Consent and Release to facilitate the DERMAdoctor Sale Transaction, issuing Series D Warrants and New Notes convertible into common stock, triggering an anti-dilution adjustment to the Series C Preferred Stock conversion price.

10-Q filing | 6.5M shares outstanding

10-Q filing | 4.2M shares outstanding

S-1 filing: This S-1 filing relates to the resale of up to 7,615,392 shares of NovaBay Pharmaceuticals, Inc.'s common stock by selling stockholders, issuable upon conversion of debentures and exercise of warrants.

S-1 filing: This prospectus relates to the resale of up to 7,863,570 shares of NovaBay Pharmaceuticals, Inc.'s common stock by selling stockholders.

S-1/A filing: This S-1/A filing registers the resale of up to 327,860 shares of common stock issuable upon the exercise of outstanding Common Stock warrants and also discusses a recent private placement.

10-Q filing | 2.0M shares outstanding

8-K filing: NovaBay Pharmaceuticals entered into a Securities Purchase Agreement for a private placement involving convertible debentures and warrants, with gross proceeds expected to be $3.0 million. ($6.0M proceeds)

S-1/A filing: This S-1/A filing registers the resale of up to 327,860 shares of NovaBay Pharmaceuticals, Inc.'s common stock issuable upon the exercise of outstanding Common Stock warrants with an exercise price of $6.30.

10-K filing | 2.0M shares outstanding

S-1 filing: This prospectus relates to the resale of up to 327,860 shares of NovaBay Pharmaceuticals, Inc.'s common stock, issuable upon the exercise of outstanding Common Stock warrants with a per share exercise price equal to $6.30.

S-1 filing: This prospectus relates to the resale of up to 1,548,502 shares of NovaBay Pharmaceuticals, Inc.'s common stock, issuable upon: (i) the conversion of shares of our Series C Non-Voting Convertible Preferred Stock (ii) the exercise of our short-term Series A-1 warrants to purchase Common Stock and (iii) the exercise of our long-term Series A-2 warrants to purchase Common Stock.

10-Q filing | 65.0M shares outstanding

S-1 filing: This prospectus relates to the resale of up to 35,510,720 shares of NovaBay Pharmaceuticals, Inc.'s common stock upon the conversion of shares of their Series B Non-Voting Convertible Preferred Stock.

10-Q filing | 52.7M shares outstanding

10-Q filing | 50.1M shares outstanding

10-K filing | 43.7M shares outstanding

S-1 filing: This S-1 filing relates to the resale of up to 37,500,000 shares of common stock by selling stockholders upon the exercise of outstanding common stock warrants.

S-1 filing: This S-1 filing relates to the resale of up to 37,500,000 shares of NovaBay Pharmaceuticals, Inc.'s common stock upon the conversion of Series B Non-Voting Convertible Preferred Stock.

10-Q filing | 44.9M shares outstanding

8-K filing: NovaBay Pharmaceuticals, Inc. closed a private placement on November 2, 2021, selling 15,000 shares of Series B non-voting convertible preferred stock convertible into 37,500,000 shares of common stock and warrants exercisable for 37,500,000 shares of common stock for gross proceeds of $15.0 million. ($15.0M proceeds)

8-K filing: NovaBay Pharmaceuticals, Inc. entered into a Securities Purchase Agreement to sell 15,000 shares of Series B non-voting convertible preferred stock and Common Stock warrants exercisable for 37,500,000 shares of Common Stock in a private placement for an aggregate purchase price of $15,000,000. ($15.0M proceeds)

10-Q filing | 44.6M shares outstanding

10-Q filing | 41.8M shares outstanding

S-3/A filing: The company may offer and sell up to $30,000,000 of any combination of common stock, preferred stock, debt securities, warrants or units.

S-3 filing: NovaBay Pharmaceuticals files an S-3 form to register the offering of up to $30,000,000 in common stock, preferred stock, debt securities, warrants, or units.

10-K filing | 41.8M shares outstanding

10-Q filing | 40.1M shares outstanding

8-K filing: NovaBay Pharmaceuticals reports pro forma stockholders' equity of approximately $14 million as of October 12, 2020, believing it has regained compliance with NYSE American listing requirements.

8-K filing: NovaBay Pharmaceuticals, Inc. entered into a First Amendment to its Services Agreement with TLF Bio Innovation Lab, LLC, modifying the terms of Equity Awards for TLF Bio Innovation's services as product manager for CelleRx.

S-3 filing: This prospectus relates to the resale of up to 6,898,566 Warrant Shares to be issued upon the exercise of the Warrants issued to the Selling Securityholders in the Warrant Reprice Transaction.

10-Q filing | 41.7M shares outstanding

8-K filing: NovaBay Pharmaceuticals, Inc. entered into a Services Agreement with TLF Bio Innovation Lab, LLC and a Securities Purchase Agreement in which the Company sold 1,000 shares of its common stock for $1,030. ($0.0M proceeds)

S-1 filing: This S-1 filing relates to the resale of 10,205,644 shares of NovaBay Pharmaceuticals Inc.'s common stock held by two major stockholders.

10-Q filing | 28.0M shares outstanding

10-K filing | 28.0M shares outstanding

POS AM filing: This POS AM filing deregisters 870,973 shares of common stock due to the termination of the SPA, as Triton LP no longer has the opportunity to purchase and resell the shares.